Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1018 Pandemic Influenza Vaccine Study
NCT05972174Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of mRNA-1018 in pandemic influenza, sponsored by Moderna Inc. Started Jul 2023; status: completed.
02
Drugs
mRNA-1018
03
Conditions
pandemic influenza
Beyond the preview
Go deeper on NCT05972174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972174.